APM - Aptorum Group rockets 1294% on launch of infectious disease liquid biopsy unit
Thinly traded nano cap Aptormum Group (APM) balloons 1,294% premarket on robust volume in reaction to the launch of a subsidiary, Aptorum Innovations, focused on infectious disease liquid biopsy diagnostics.Concurrently, it has in-licensed exclusive rights to co-develop novel molecular-based rapid pathogen identification and detection diagnostics ((RPIDD)) technology with Accelerate Technologies Pte Ltd, the commercialization arm of Singapore's Agency for Science, Technology and Research.Financial terms are not disclosed.Quant rating is Very Bearish.
For further details see:
Aptorum Group rockets 1,294% on launch of infectious disease liquid biopsy unit